Filing Flows › Vivos Therapeutics (VVOS) › Who owns the stock
Who owns Vivos Therapeutics (VVOS) stock
26 funds reported Vivos Therapeutics (VVOS) shares in their latest 13F filings, worth $837K in all. The largest holder is Vanguard Group ($617K). Last quarter 5 funds added to their stakes and 8 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Vanguard Group | 304,161 | $617K | increase | 2025-12-31 |
| Geode Capital Management, LLC | 85,001 | $39K | decrease | 2026-06-30 |
| IHT Wealth Management, LLC | 76,736 | $35K | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 60,629 | $28K | decrease | 2026-06-30 |
| Commonwealth Equity Services, LLC | 42,500 | $19K | unchanged | 2026-06-30 |
| UBS Group AG | 39,154 | $18K | increase | 2026-06-30 |
| BlackRock | 27,817 | $13K | unchanged | 2026-06-30 |
| State Street | 24,922 | $11K | unchanged | 2026-06-30 |
| Sequoia Financial Advisors, LLC | 24,000 | $11K | unchanged | 2026-06-30 |
| Vanguard Fiduciary Trust | 23,432 | $11K | decrease | 2026-06-30 |
| Northern Trust | 20,775 | $9K | increase | 2026-06-30 |
| StoneX Group | 28,661 | $6K | new | 2026-09-30 |
| Centurion Wealth Management LLC | 35,684 | $5K | unchanged | 2026-09-30 |
| B. Riley Wealth Advisors | 35,066 | $5K | decrease | 2026-09-30 |
| Susquehanna International Group, LLP | 10,075 | $5K | new | 2026-06-30 |
Vivos Therapeutics' latest quarter
Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%, net loss $5.5M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most VVOS stock?
By the latest 13F filings: Vanguard Group ($617K); Geode Capital Management, LLC ($39K); IHT Wealth Management, LLC ($35K); Vanguard Capital Management LLC ($28K); Commonwealth Equity Services, LLC ($19K).
What is the short interest in VVOS?
2,358,382 shares were sold short at the 2026-10-15 settlement, -17.66% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.